• 4-MUG: A Functional Readout for Lysosomal GCase

  2026-09-10

  4-Methylumbelliferyl-β-D-Glucopyranoside converts β-glucosidase activity into a quantitative fluorescent signal. This guide explains how to use 4-MUG to interpret lysosomal function, GBA1 mRNA rescue, and Gaucher disease models without confusing enzyme abundance with catalytic performance.

• Triamcinolone (B1859): Practical Research Workflow

  2026-09-10

  Triamcinolone (SKU B1859) provides a high-purity synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solvent selection, stock handling, controls, and quality checks; the material is not intended for diagnostic, therapeutic, clinical, or unsupported in vivo use.

• RepSox for iPSC Platelet Differentiation

  2026-09-09

  RepSox provides a precise way to test ALK5-dependent TGF-β signaling during iPSC reprogramming and platelet-lineage differentiation. This evidence-aware workflow combines a reported 25 μM, 3-day exposure with the latest high-yield megakaryocyte protocol to separate validated findings from experiments that still require optimization.

• Gemcitabine Workflows for DNA Damage Research

  2026-09-09

  Gemcitabine enables controlled studies of DNA synthesis inhibition, checkpoint activation, and apoptosis across cancer models. This workflow connects practical dosing and assay design with the TAK1–YAP stemness findings reported in gastric cancer research, while clearly separating established evidence from hypothesis-generating applications.

• Triamcinolone Research Workflow and QC Guide

  2026-09-08

  Triamcinolone provides a defined synthetic glucocorticoid agonist for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solvent selection, stock preparation, storage, and assay controls; the compound is for scientific research only and must not be used for diagnostic, therapeutic, or clinical purposes.

• ERAD-Engaging Chimeras for TM Protein Degradation

  2026-09-08

  Song and colleagues establish ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform that recruits the ER E3 ligase SYVN1 to eliminate transmembrane proteins. The study reports highly effective PD-L1 degradation, tumor suppression in vivo, and an expanded application to mutant huntingtin, providing a mechanistically distinct alternative to lysosome-directed strategies.

• Structure-Guided Proteomimetics for SARS-CoV-2

  2026-09-07

  The reference study develops constrained proteomimetics that reproduce key recognition elements of the hACE2 surface engaged by the SARS-CoV-2 Spike receptor-binding domain. By combining stapled helical and macrocyclic β-sheet mimetics, the authors generated compound 28, which disrupted viral entry while showing stability and low epithelial permeability consistent with possible intranasal delivery.

• Maternal IL-17A and Neonatal GBS Risk

  2026-09-07

  A prospective Moroccan mother–newborn cohort study identifies reduced maternal IL-17A responses as a potential marker of invasive neonatal Group B Streptococcus disease. By combining cytokine profiling with ex vivo TLR4 and TLR1/2 stimulation, the study connects maternal inflammatory phenotypes with vertical-transmission risk while defining important limits for clinical translation.

• Camostat Mesilate: Reliable Assay Design

  2026-09-05

  Learn how Camostat Mesilate, SKU B2082, can be incorporated into viability, proliferation, cytotoxicity, and fibrosis-related workflows without confusing mechanism-specific effects with cell injury. The guide covers assay controls, stock preparation, protocol parameters, interpretation, and practical supplier-selection criteria.

• NF 340: P2Y11 Antagonist Research Guide

  2026-09-04

  NF 340 is a selective P2Y11 antagonist for studying purinergic GPCR signaling in cellular models. In a breast cancer study, NF 340 reversed QPRT-associated invasiveness and myosin light-chain phosphorylation, while product specifications define its identity, storage, and research-use boundaries.

• Thiazovivin (A5506): ROCK Inhibitor Workflow

  2026-09-04

  Thiazovivin (A5506) is a research-use ROCK inhibitor for workflows involving fibroblast reprogramming, induced pluripotent stem cell generation, and human embryonic stem cell recovery after trypsinization. This dossier-based guide covers preparation, storage, controls, and troubleshooting; it is not a dosing guide and the compound is not intended for diagnostic, therapeutic, or medical use.

• Tioconazole Workflows for Antifungal Research

  2026-09-03

  Build reproducible Tioconazole concentration-response studies, ergosterol-focused assays, and fungal infection models with practical controls for solubility, vehicle effects, and exposure time. The workflow also shows how a recent AML DNA-repair study can inform assay design without implying that Tioconazole acts on the ATG4B pathway.

• Praeruptorin A, DMT1, and Ferroptosis in DIC

  2026-09-03

  A 2025 European Journal of Medicinal Chemistry study used ferrous-ion screening to identify Praeruptorin A as a candidate suppressor of DMT1-linked ferroptosis in doxorubicin-induced cardiomyopathy. The work connects an Fe²⁺-centered discovery assay with cellular, animal, and tumor-combination models, while also defining important limits for translating the findings beyond preclinical cardiotoxicity research.

• DMH1: A Translational Lever for ALK2 Biology

  2026-09-02

  DMH1 offers translational researchers a selective ALK2 inhibitor for connecting BMP-driven cell-state control with organoid engineering and non-small cell lung cancer research. This article outlines the mechanism, validation strategy, protocol considerations, competitive advantages, and limits of using DMH-1 to interrogate BMP signaling without confusing pathway modulation with clinical evidence.

• PDT and STING Activation Suppress Tumor Recurrence

  2026-09-02

  The 2024 ACS Applied Materials & Interfaces study developed GM@P, a nanoparticle combining MHI148-targeted photodynamic therapy with the STING agonist 2′3′-cGAMP. The platform linked tumor-cell ablation, immunogenic cell death, type I interferon induction, dendritic-cell maturation, and CD8+ T-cell infiltration to inhibit breast cancer growth, metastasis, and recurrence in preclinical models.

8406 records 1/561 page Next 12345 下5页 Last page